The text starts here.

News Release

February 24, 2005

Eisai Announces Establishment of its Pharmaceuticals
Marketing Subsidiary in Italy

Eisai Co., Ltd. (Headquarters: Tokyo, President: Haruo Naito) announced that on February 21, 2005, it established a pharmaceuticals marketing subsidiary, Eisai S.r.l. (Eisai Società a responsabilità limitata) in Italy. Eisai S.r.l. is fully owned by Eisai Europe Limited (Headquarters: London, President: Yutaka Tsuchiya).

In Italy, Eisai S.r.l. will sell and promote pharmaceuticals including Zonegran(R), an anti-epileptic drug whose MAA (Marketing Authorization Application) has been submitted to EMEA (European Medicines Agency), and rufinamide, another anti-epileptic drug whose MAA is planned to be submitted in FY2004.

Eisai already has marketing subsidiaries in the U.K., France, Germany and Spain. The company aims at expanding its sales network for its own products in EU countries. The pharmaceutical market in Italy is the fourth largest in Europe and it is expected to grow rapidly. The newly established subsidiary company will establish a business structure in Italy and will provide a stable supply of quality products and appropriate product information for safe and proper usage to meet the medical needs of patients in Italy.

[Company Outline]
Company Name:Eisai Società a responsabilità limitata
Capital:3.5 million EUR (approximately 470 million yen)
Location:Milan, Italy
Managing Director:Yutaka Tsuchiya
Operations: Application for pharmaceuticals registration, promotion/sale of pharmaceuticals
Form: Limited company

Contacts :
Eisai Co., Ltd.
Corporate Communications Department
Phone 03-3817-5120 (Tokyo)